Antibody discovery is an important component for early-stage research studies, diagnostics, and therapeutics. Hybridoma technology has been the forefront tool in generating monoclonal antibodies but is time consuming and costly. MedGenome’s proprietary HitMab platform now enables researchers to identify antigen-specific antibodies in less than 6 months’ time.
Streamlined High-Throughput Monoclonal AntiBody discovery service
|HitMab Technology||Hybridoma Technology|
|Validated Recombinant Antibodies delivered|
|Generate antibodies for low or poorly immunogenic proteins|
|Results in less than 6 months|
Reduce your wait time from 8-10 months with traditional Hybridoma technology to 4-6 month using HitMab service.
MedGenome Inc.’s Monoclonal Antibody Discovery Services
Antibody discovery is important for early stage research studies, diagnostics and therapeutics. Hybridoma technology has been the mainstay to generate monoclonal antibodies. MedGenome has streamlined antibody discovery using high-throughput single B cell receptor sequencing and a recently licensed proprietary platform, HiTMab* (High-throughput monoclonal antibody discovery).